Research programme: targeted cancer diagnostics and therapeutics - ImaRx TherapeuticsAlternative Names: MRX 960
Latest Information Update: 14 May 2007
At a glance
- Originator ImaRx Therapeutics
- Class Diagnostic agents
- Mechanism of Action Diagnostic imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Oct 2003 Preclinical trials in Cancer diagnosis in USA (Injection)
- 31 Oct 2003 Preclinical trials in Cancer in USA (Injection)